CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference.

Go here to read the rest:
Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh